Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers

Yong Zang, Suyu Liu, Ying Yuan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Targeted therapy revolutionizes the way that physicians treat cancer and other diseases, enabling them to select individualized treatment adaptively according to the patient's biomarker profile. The implementation of targeted therapy requires that the biomarkers are accurately measured, which may not always be feasible in practice. We propose two optimal marker-adaptive trial designs in which the biomarkers are subject to measurement errors. The first design focuses on a patient's individual benefit and minimizes the treatment assignment error so that each patient has the highest probability of being assigned to the treatment that matches his or her true biomarker status. The second design focuses on the group benefit, which maximizes the overall response rate for all the patients enrolled in the trial. We develop a Wald test to evaluate the treatment effects for marker subgroups at the end of the trial and derive the corresponding asymptotic power function. Simulation studies and an application to a lymphoma cancer trial show that the optimal designs proposed achieve our design goal and obtain desirable operating characteristics.

Original languageEnglish (US)
Pages (from-to)635-650
Number of pages16
JournalJournal of the Royal Statistical Society. Series C: Applied Statistics
Volume64
Issue number4
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Adaptive Design
Biomarkers
Therapy
Cancer
Wald Test
Asymptotic Power
Operating Characteristics
Power Function
Treatment Effects
Measurement Error
Assignment
Maximise
Simulation Study
Subgroup
Minimise
Design
Evaluate

Keywords

  • Marker-adaptive design
  • Measurement error
  • Optimal design
  • Personalized medicine
  • Power

ASJC Scopus subject areas

  • Statistics and Probability
  • Statistics, Probability and Uncertainty

Cite this

Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers. / Zang, Yong; Liu, Suyu; Yuan, Ying.

In: Journal of the Royal Statistical Society. Series C: Applied Statistics, Vol. 64, No. 4, 01.08.2015, p. 635-650.

Research output: Contribution to journalArticle

@article{3dd5098d566647ec91d278d5ae4a9f9d,
title = "Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers",
abstract = "Targeted therapy revolutionizes the way that physicians treat cancer and other diseases, enabling them to select individualized treatment adaptively according to the patient's biomarker profile. The implementation of targeted therapy requires that the biomarkers are accurately measured, which may not always be feasible in practice. We propose two optimal marker-adaptive trial designs in which the biomarkers are subject to measurement errors. The first design focuses on a patient's individual benefit and minimizes the treatment assignment error so that each patient has the highest probability of being assigned to the treatment that matches his or her true biomarker status. The second design focuses on the group benefit, which maximizes the overall response rate for all the patients enrolled in the trial. We develop a Wald test to evaluate the treatment effects for marker subgroups at the end of the trial and derive the corresponding asymptotic power function. Simulation studies and an application to a lymphoma cancer trial show that the optimal designs proposed achieve our design goal and obtain desirable operating characteristics.",
keywords = "Marker-adaptive design, Measurement error, Optimal design, Personalized medicine, Power",
author = "Yong Zang and Suyu Liu and Ying Yuan",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/rssc.12092",
language = "English (US)",
volume = "64",
pages = "635--650",
journal = "Journal of the Royal Statistical Society. Series C: Applied Statistics",
issn = "0035-9254",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers

AU - Zang, Yong

AU - Liu, Suyu

AU - Yuan, Ying

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Targeted therapy revolutionizes the way that physicians treat cancer and other diseases, enabling them to select individualized treatment adaptively according to the patient's biomarker profile. The implementation of targeted therapy requires that the biomarkers are accurately measured, which may not always be feasible in practice. We propose two optimal marker-adaptive trial designs in which the biomarkers are subject to measurement errors. The first design focuses on a patient's individual benefit and minimizes the treatment assignment error so that each patient has the highest probability of being assigned to the treatment that matches his or her true biomarker status. The second design focuses on the group benefit, which maximizes the overall response rate for all the patients enrolled in the trial. We develop a Wald test to evaluate the treatment effects for marker subgroups at the end of the trial and derive the corresponding asymptotic power function. Simulation studies and an application to a lymphoma cancer trial show that the optimal designs proposed achieve our design goal and obtain desirable operating characteristics.

AB - Targeted therapy revolutionizes the way that physicians treat cancer and other diseases, enabling them to select individualized treatment adaptively according to the patient's biomarker profile. The implementation of targeted therapy requires that the biomarkers are accurately measured, which may not always be feasible in practice. We propose two optimal marker-adaptive trial designs in which the biomarkers are subject to measurement errors. The first design focuses on a patient's individual benefit and minimizes the treatment assignment error so that each patient has the highest probability of being assigned to the treatment that matches his or her true biomarker status. The second design focuses on the group benefit, which maximizes the overall response rate for all the patients enrolled in the trial. We develop a Wald test to evaluate the treatment effects for marker subgroups at the end of the trial and derive the corresponding asymptotic power function. Simulation studies and an application to a lymphoma cancer trial show that the optimal designs proposed achieve our design goal and obtain desirable operating characteristics.

KW - Marker-adaptive design

KW - Measurement error

KW - Optimal design

KW - Personalized medicine

KW - Power

UR - http://www.scopus.com/inward/record.url?scp=84934813028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934813028&partnerID=8YFLogxK

U2 - 10.1111/rssc.12092

DO - 10.1111/rssc.12092

M3 - Article

AN - SCOPUS:84934813028

VL - 64

SP - 635

EP - 650

JO - Journal of the Royal Statistical Society. Series C: Applied Statistics

JF - Journal of the Royal Statistical Society. Series C: Applied Statistics

SN - 0035-9254

IS - 4

ER -